Evidence map›Paper›PMID 40103230›Full record

ArticleNucleic acids research2025

Small molecule inhibitors of hnRNPA2B1-RNA interactions reveal a predictable sorting of RNA subsets into extracellular vesicles.

Jessica Corsi, Pouriya Sharbatian Semnani, Daniele Peroni, Romina Belli, Alessia Morelli, Michelangelo Lassandro, Viktoryia Sidarovich, Valentina Adami, Chiara Valentini, Paolo Cavallerio and 7 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jessica CorsiLaboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Pouriya Sharbatian SemnaniLaboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Daniele PeroniMS Core Facility, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Romina BelliMS Core Facility, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Alessia MorelliLaboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Michelangelo LassandroLaboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Viktoryia SidarovichHTS Core Facility, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Valentina AdamiHTS Core Facility, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Chiara ValentiniNGS Core Facility, Department of Cellular, Computational and Integrative Biomedicine CIBIO, University of Trento, 38122 Trento, Italy.
Paolo CavallerioNGS Core Facility, Department of Cellular, Computational and Integrative Biomedicine CIBIO, University of Trento, 38122 Trento, Italy.
Julian GrosskreutzExcellence Cluster Precision Medicine in Inflammation, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany.
Fabrizio FabbianoLaboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Dajana GrossmannTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany.
Andreas HermannTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany.ORCID 0000-0002-7364-7791
Gianluca TellLaboratory of Molecular Biology and DNA repair, Department of Medicine (DMED), University of Udine, Piazzale M. Kolbe 4, 33100 Udine, Italy.ORCID 0000-0001-8845-6448
Manuela BassoLaboratory of Transcriptional Neurobiology, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.ORCID 0000-0002-9278-8960
Vito G D'AgostinoLaboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.ORCID 0000-0003-3379-2254

Funding

Deutschen Gesellschaft für Parkinson und BewegungsstörungenDFGEuropean Regional Development FundEuropean Union - Next Generation EUFondazione Cassa di Risparmio Trento e Rovereto, CaritroHermann und Lilly Schilling-Stiftung für medizinische ForschungItalian Ministry of Health GR-2016-02361552Italian Ministry of University and Research
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are cell-secreted membranous particles contributing to intercellular communication. Coding and noncoding RNAs can be detected as EV cargo, and RNA-binding proteins (RBPs), such as hnRNPA2B1, have been circumstantially implicated in EV-RNA sorting mechanisms. However, the contribution of competitive RBP-RNA interactions responsible for RNA-sorting outcomes is still unclear, especially for predicting the EV-RNA content. We designed a reverse proteomic analysis exploiting the EV-RNA to identify intracellular protein binders in vitro. Using cells expressing a recombinant hnRNPA2B1 to normalize competitive interactions, we prioritized a network of heterogeneous nuclear ribonucleoproteins and purine-rich RNA sequences subsequently validated in secreted EV-RNA through short fluorescent RNA oligos. Then, we designed a GGGAG-enriched RNA probe that efficiently interacted with a full-length human hnRNPA2B1 protein. We exploited the interaction to conduct a pharmacological screening and identify inhibitors of the protein-RNA binding. Small molecules were orthogonally validated through biochemical and cell-based approaches. Selected drugs remarkably impacted secreted EV-RNAs and reduced an RNA-dependent, EV-mediated paracrine activation of NF-kB in recipient cells. These results demonstrate the relevance of post-transcriptional mechanisms for EV-RNA sorting and the possibility of predicting the EV-RNA quality for developing innovative strategies targeting discrete paracrine functions.

Indexed as

Extracellular VesiclesHeterogeneous-Nuclear Ribonucleoprotein Group A-BRNASmall Molecule LibrariesHEK293 CellsHumansNF-kappa BProtein BindingProteomicsRNA-Binding ProteinsHeterogeneous-Nuclear Ribonucleoprotein Group A-BhnRNP A2NF-kappa BRNARNA-Binding ProteinsSmall Molecule Libraries

Identifiers

PMID40103230
PMCPMC11915509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.